First paediatric EC approval of HIV drug
European Pharmaceutical Review
NOVEMBER 30, 2022
At Week two or Week 4, selected participants were given a pharmacokinetic (PK) evaluation to confirm the dosage that the participants would receive. In this study, no new adverse reactions (ARs) have been observed in paediatric subjects aged two years and older living with HIV-1 compared to adults. Treatment cohort 3.
Let's personalize your content